Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Early T-Cell Precursor Acute Lymphoblastic Leukemia (ETP-ALL) Is a High-Risk Subtype in Adults

Nitin Jain, MD, Audrey Lamb, BS, Susan M. O'Brien, MD, Farhad Ravandi, MD, Marina Konopleva, MD PhD, Elias Jabbour, Zhuang Zuo, MD PhD, Jeffrey L. Jorgensen, MD PhD, Pei Lin, MD, Sherry Pierce, BSN, BA, Deborah A Thomas, MD, Michael Rytting, MD, Gautam Borthakur, MD, Tapan Kadia, MD, Jorge E. Cortes, MD, Hagop M. Kantarjian, MD, Joseph D Khoury, MD

Blood (2015) 126 (23): 1418.

https://doi.org/10.1182/blood.V126.23.1418.1418

Published: 2015

Journal Articles

Incidence of Central Nervous System (CNS) Relapse in De Novo Adult Acute Lymphoblastic Leukemia (ALL)

Blood (2014) 124 (21): 940.

https://doi.org/10.1182/blood.V124.21.940.940

Published: 2014

Journal Articles

Incidence and Outcome In Adults With Acute Lymphoblastic Leukemia With Primary Central Nervous System Involvement

Muhamed Baljevic, MD, Hagop M Kantarjian, MD, Deborah Thomas, MD, Michael Rytting, MD, Jyothsna Dasarathula, MBBS, Gautam Borthakur, MD, Jan A. Burger, MD, PhD, Farhad Ravandi, MD, Elias Jabbour, MD, Marina Konopleva, MD, PhD, Sherry Pierce, Mark Brandt, Susan O'Brien, MD, Jorge E. Cortes, MD

Blood (2013) 122 (21): 2639.

https://doi.org/10.1182/blood.V122.21.2639.2639

Published: 2013

Journal Articles

Augmented Hyper-CVAD in Adult ALL Salvage Therapy: The MDACC Experience of Hyper-CVAD Using Dose-Intense Vincristine, Dexamethasone, and Pegaspargase.

Mohamad Ayoubi, MD, Deborah A. Thomas, MD, Hagop Kantarjian, MD, Susan O'Brien, MD, Farhad Ravandi, MD, Guillermo Garcia-Manero, MD, Srdan Verstovsek, MD, Michael Rytting, MD, Gautam Borthakur, MD, Tapan Kadia, MD, Steven M. Kornblau, MD, Michael Andreeff, MD, PhD, Jenny Feliu, RN, Stefan Faderl, MD

Blood (2009) 114 (22): 2031.

https://doi.org/10.1182/blood.V114.22.2031.2031

Published: 2009

Journal Articles

Intensively Timed Induction (ITI) Chemotherapy in Adults with Acute Myelogenous Leukemia (AML).

Michael Rytting, MD, Srdan Verstovsek, M.D., Ph.D., Guillermo Garcia-Manero, M.D., Farhad Ravandi-Kashani, M.D., Sherry Pierce, R.N., Elihu Estey, M.D.

Blood (2007) 110 (11): 1851.

https://doi.org/10.1182/blood.V110.11.1851.1851

Published: 2007

Journal Articles

A Novel Therapy of Clofarabine in Combination with Etoposide and Cyclophosphamide Shows Activity in Pediatric Patients with Refractory or Relapsed Acute Leukemia.

Nobuko Hijiya, MD, Paul Gaynon, MD, Manuel Fernandez, Michael Rytting, MD, Roland Chu, MD, Elly Barry, MD, Blythe Thomson, MD, Todd Cooper, MD, Richard Kadota, MD, Stanley Chaleff, MD, Peter Steinherz, MD, Rekha Abichandani, MD, William Carroll, MD

Blood (2007) 110 (11): 883.

https://doi.org/10.1182/blood.V110.11.883.883

Published: 2007

Journal Articles

Intensification of Hyper-CVAD with L-Asparaginase, Vincristine, and Dexamethasone ("Augmented Hyper-CVAD") Has Activity in Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL).

Stefan Faderl, MD, Deborah A. Thomas, MD, Farhad Ravandi, MD, Guillermo Garcia-Manero, MD, Miloslav Beran, MD PhD, Michael Rytting, MD, Charles A. Koller, MD, Srdan Verstovsek, MD PhD, Gautam Borthakur, MD, Michael Andreeff, MD PhD, Steve Kornblau, MD, Susan O’Brien, MD, Khanh Vu, MD, Monica Kwari, RN, Jennie Bretz, RN, Hagop M. Kantarjian, MD

Blood (2007) 110 (11): 4324.

https://doi.org/10.1182/blood.V110.11.4324.4324

Published: 2007

Journal Articles

Adaptation of Augmented Berlin-Frankfurt-Munster (ABFM) Therapy in Adolescents and Young Adults with Acute Lymphoblastic Leukemia (ALL).

Michael Rytting, MD, Deborah Thomas, M.D., Hagop Kantarjian, M.D., Jorge Cortes, M.D., Gautam Borthakur, M.D., William Wierda, M.D., Cesar Nunez, M.D., Steven Kornblau, M.D., Farhad Ravandi, M.D., Robert Wells, M.D., Muriera Brenda, R.N., Franklin Anna, M.D., Susan O’Brien, M.D.

Blood (2007) 110 (11): 4342.

https://doi.org/10.1182/blood.V110.11.4342.4342

Published: 2007

Journal Articles

Minimal Residual Disease (MRD) after Frontline Therapy in Adolescent and Young Adult (AYA) Patients with Acute Lymphoblastic Leukemia (ALL) Treated on Two Separate Regimens.

Michael Rytting, MD, Deborah Thomas, M.D., Jeffrey Jorgensen, M.D., Hagop Kantarjian, M.D., Rebecca Garris, Brenda Muriera, R.N., Susan O’Brien, M.D.

Blood (2007) 110 (11): 4344.

https://doi.org/10.1182/blood.V110.11.4344.4344

Published: 2007

Journal Articles

Toxicities of Intravenous (IV) Pegasparaginase (ONCASPAR®) in Adults with Acute Lymphoblastic Leukemia (ALL).

Anjali Advani, MD, Marc Earl, PharmD, Dan Douer, MD, Michael Rytting, MD, Archie Bleyer, MD

Blood (2007) 110 (11): 2811.

https://doi.org/10.1182/blood.V110.11.2811.2811

Published: 2007

Journal Articles

Phase I Study of 5-aza-2′-Deoxycitidine, Alone or in Combination with Hyper-CVAD, in Relapsed or Refractory Acute Lymphocytic Leukemia (ALL).

Guillermo Garcia-Manero, MD, Deborah Thomas, MD, Michael Rytting, MD, Patrick Zweidler-McKay, MD, Zeev Estrov, MD, Devri L. Brown, MD, Hui Yang, MD, Hagop Kantarjian, MD, Susan O’Brien, MD

Blood (2007) 110 (11): 2826.

https://doi.org/10.1182/blood.V110.11.2826.2826

Published: 2007

Journal Articles

Augmented Hyper-CVAD in Acute Lymphoblastic Leukemia (ALL): The MDACC Experience with Intensified L-Asparaginase and Vincristine in Adult ALL Salvage.

Stefan Faderl, MD, Deborah A. Thomas, MD, Guillermo Garcia-Manero, MD, Farhad Ravandi, MD, Miloslav Beran, MD, PhD, Michael Rytting, MD, Charles A. Koller, MD, Srdan Verstovsek, MD, PhD, Gautam Borthakur, MD, Michael Andreeff, MD, PhD, Steve Kornblau, MD, Khanh Vu, MD, Rita Jarmon, R.N., Hagop M. Kantarjian, MD

Blood (2005) 106 (11): 1840.

https://doi.org/10.1182/blood.V106.11.1840.1840

Published: 2005

Journal Articles

Final Results of a Phase I/II Study of the Combination of the Hypomethylating Agent 5-aza-2′-Deoxycytidine (DAC) and the Histone Deacetylase Inhibitor Valproic Acid (VPA) in Patients with Leukemia.

Guillermo Garcia-Manero, MD, Hagop Kantarjian, MD, Blanca Sanchez-Gonzalez, MD, Hui Yang, MD, PhD, Gary Rosner, PhD, Srdan Verstovsek, MD, Michael Rytting, MD, Farhad Ravandi, MD, Stefan Faderl, MD, Zeev Estrov, MD, Jorge Cortes, MD, Susan O’Brien, MD, Jackie Fiorentino, MD, Jean-Pierre Issa, MD

Blood (2005) 106 (11): 408.

https://doi.org/10.1182/blood.V106.11.408.408

Published: 2005

Journal Articles

Effect of Age on Prognosis in Childhood Acute Myeloid Leukemia.

Bassem I. Razzouk, MD, Elihu Estey, MD, Stanley B. Pounds, Ph.D, Shelly Lensing, MS, Sherry Pierce, MS, Mark Brandt, MS, Jeffrey E. Rubnitz, MD, Raul C. Ribeiro, MD, Michael Rytting, MD, Ching-Hon Pui, MD, Hagop M. Kantarjian, MD, Sima C. Jeha, MD

Blood (2004) 104 (11): 1064.

https://doi.org/10.1182/blood.V104.11.1064.1064

Published: 2004

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Early T-Cell Precursor Acute Lymphoblastic Leukemia (ETP-ALL) Is a High-Risk Subtype in Adults

Incidence of Central Nervous System (CNS) Relapse in De Novo Adult Acute Lymphoblastic Leukemia (ALL)

Incidence and Outcome In Adults With Acute Lymphoblastic Leukemia With Primary Central Nervous System Involvement

Augmented Hyper-CVAD in Adult ALL Salvage Therapy: The MDACC Experience of Hyper-CVAD Using Dose-Intense Vincristine, Dexamethasone, and Pegaspargase.

Intensively Timed Induction (ITI) Chemotherapy in Adults with Acute Myelogenous Leukemia (AML).

A Novel Therapy of Clofarabine in Combination with Etoposide and Cyclophosphamide Shows Activity in Pediatric Patients with Refractory or Relapsed Acute Leukemia.

Intensification of Hyper-CVAD with L-Asparaginase, Vincristine, and Dexamethasone ("Augmented Hyper-CVAD") Has Activity in Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL).

Adaptation of Augmented Berlin-Frankfurt-Munster (ABFM) Therapy in Adolescents and Young Adults with Acute Lymphoblastic Leukemia (ALL).

Minimal Residual Disease (MRD) after Frontline Therapy in Adolescent and Young Adult (AYA) Patients with Acute Lymphoblastic Leukemia (ALL) Treated on Two Separate Regimens.

Toxicities of Intravenous (IV) Pegasparaginase (ONCASPAR®) in Adults with Acute Lymphoblastic Leukemia (ALL).

Phase I Study of 5-aza-2′-Deoxycitidine, Alone or in Combination with Hyper-CVAD, in Relapsed or Refractory Acute Lymphocytic Leukemia (ALL).

Augmented Hyper-CVAD in Acute Lymphoblastic Leukemia (ALL): The MDACC Experience with Intensified L-Asparaginase and Vincristine in Adult ALL Salvage.

Final Results of a Phase I/II Study of the Combination of the Hypomethylating Agent 5-aza-2′-Deoxycytidine (DAC) and the Histone Deacetylase Inhibitor Valproic Acid (VPA) in Patients with Leukemia.

Effect of Age on Prognosis in Childhood Acute Myeloid Leukemia.

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only